ProKidney (PROK) Earnings Date & Reports

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PROK is expected to report earnings to rise 5.53% to -15 cents per share on November 16

Q3'26

Est.

$-0.16

Q2'26

Missed

by $0.01

Q4'25

Beat

by $0.01

Q3'25

Beat

by $0.03

Q2'25

Beat

by $0.02

The last earnings report on August 10 showed earnings per share of -15 cents, missing the estimate of -14 cents. With 1.16M shares outstanding, the current market capitalization sits at 336.37M.

View a ticker or compare two or three

PROK

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days